| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Access to information on drug regulation in the countries of Central and Eastern Europe
|
Vrhovać, Boźidar
|
|
2013
|
9 |
3 |
p. 173-178
|
article
|
| 2 |
Access to regulatory information in Malaysia – a preliminary study
|
Razak, Dzulkifli Abdul
|
|
2013
|
9 |
3 |
p. 179-186
|
article
|
| 3 |
An ISDB survey to assess the degree of transparency of drug regulatory agencies
|
Bardelay, Danielle
|
|
2013
|
9 |
3 |
p. 151-155
|
article
|
| 4 |
Author Index Volume 9 (1996)
|
|
|
2013
|
9 |
3 |
p. 219-220
|
article
|
| 5 |
Drug regulation and the tradition of secrecy
|
Dukes, M.N. Graham
|
|
2013
|
9 |
3 |
p. 143-149
|
article
|
| 6 |
Globalisation of drug regulation and drug regulators in developing countriesGroping in the dark even when there is a light switch; an example from Sri Lanka
|
Weerasuriya, K.
|
|
2013
|
9 |
3 |
p. 187-193
|
article
|
| 7 |
International harmonisation – the need for transparency
|
Hodgkin, Catherine
|
|
2013
|
9 |
3 |
p. 195-199
|
article
|
| 8 |
Secrecy and medicines
|
Medawar, Charles
|
|
2013
|
9 |
3 |
p. 133-141
|
article
|
| 9 |
Secrecy in drug regulationLicensing documentation on the Norplant® contraceptive
|
Ollila, Eeva
|
|
2013
|
9 |
3 |
p. 161-172
|
article
|
| 10 |
Side effects: freedom of information and the communication of doubt
|
Herxheimer, Andrew
|
|
2013
|
9 |
3 |
p. 201-210
|
article
|
| 11 |
Statement of the International Working Group on transparency and accountability in drug regulation
|
(HAI) Health Action International and the Dag Hammarskjöld Foundation,
|
|
2013
|
9 |
3 |
p. 211-217
|
article
|
| 12 |
The case of contaminated blood products in Japan
|
Beppu, Hirokuni
|
|
2013
|
9 |
3 |
p. 157-159
|
article
|
| 13 |
Time to lift the veil of secrecy
|
|
|
2013
|
9 |
3 |
p. 131-132
|
article
|
Journal description